Modality
Fusion Protein
MOA
JAK1i
Target
TYK2
Pathway
Autophagy
Huntington's
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
Oct 2022
→ Nov 2027
Phase 3Current
NCT07126311
168 pts·Huntington's
2022-10→2027-11·Terminated
NCT04836102
657 pts·Huntington's
2025-01→TBD·Not yet recruiting
825 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-011.6y awayPh3 Readout· Huntington's
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2027-11-01 · 1.6y away
Huntington's
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07126311 | Phase 3 | Huntington's | Terminated | 168 | Mayo |
| NCT04836102 | Phase 3 | Huntington's | Not yet recr... | 657 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 |